APA (7th ed.) Citation

C, X., ZQ, L., YZ, W., JX, S., WF, L., GQ, Z., . . . J, M. (2026). Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma. Med (New York, N.Y.), 7(3), 100994. https://doi.org/10.1016/j.medj.2025.100994

Chicago Style (17th ed.) Citation

C, Xu, et al. "Patient-reported Outcomes from a Phase 2 PLATINUM Trial of Nivolumab Combination Therapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma." Med (New York, N.Y.) 7, no. 3 (2026): 100994. https://doi.org/10.1016/j.medj.2025.100994.

MLA (9th ed.) Citation

C, Xu, et al. "Patient-reported Outcomes from a Phase 2 PLATINUM Trial of Nivolumab Combination Therapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma." Med (New York, N.Y.), vol. 7, no. 3, 2026, p. 100994, https://doi.org/10.1016/j.medj.2025.100994.